Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata

Published: Mar 5, 2021 | Tags: Eli Lilly and Incyte, Report, Results, Olumiant (baricitinib), P-III, BRAVE-AA2, Study, Severe, Alopecia Areata

Takeda Reports NDA Submission to Import and Distribute Moderna's mRNA-1273 in Japan

Published: Mar 5, 2021 | Tags: Takeda, Reports, NDA, Submission, Import, Distribute, Moderna, mRNA-1273, Japan

Roche's Actemra/RoActemra (tocilizumab) Receives the US FDA's Approval as the First Biologic for Systemic Sclerosis-Associated Interstitial Lung Disease

Published: Mar 5, 2021 | Tags: Roche, Actemra/RoActemra (tocilizumab), Receives, US, FDA, Approval, First, Biologic, Systemic Sclerosis-Associated Interstitial Lung Disease

Agilent to Acquire Resolution Bioscience for $695M

Published: Mar 5, 2021 | Tags: Agilent, Acquire, Resolution Bioscience, $695M

Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

Published: Mar 5, 2021 | Tags: Lilly, Reports, Results, Tirzepatide, P-lll, SURPASS-2, Trial, Type-2 Diabetes

Amgen to Acquire Five Prime for ~$1.9B

Published: Mar 5, 2021 | Tags: Amgen, Acquire, Five Prime, ~$1.9B

Vir and GSK Provide Update on ACTIV-3 Trial of VIR-7831 in Hospitalized Adults with COVID-19

Published: Mar 4, 2021 | Tags: Vir and GSK, Provide, Update, ACTIV-3, Trial, VIR-7831, Hospitalized Adults, COVID-19

Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

Published: Mar 4, 2021 | Tags: Roche, Collaborates, Tempest, Evaluate, TPST-1120, Combination, Study, 1L, Treatment, Hepatocellular Carcinoma

Regeneron and Sanofi Report the US FDA's Acceptance of sBLA for Review of Dupixent to Treat Moderate-to-Severe Asthma in Children

Published: Mar 4, 2021 | Tags: Regeneron and Sanofi, Report, US, FDA, Acceptance, sBLA, Review, Dupixent, Treat, Moderate-to-Severe, Asthma, Children

Pfizer's Lorbrena (lorlatinib) Receives FDA's Approval for Expanding its Indication to Treat ALK-Positive Metastatic Lung Cancer

Published: Mar 4, 2021 | Tags: Pfizer, Lorbrena (lorlatinib), Receives, FDA, Approval, Expanding,  Indication, Treat, ALK-Positive Metastatic, Lung Cancer

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

Published: Mar 4, 2021 | Tags: Takeda, Signs, Exclusive, License, Agreement, Ovid, Soticlestat, Treat Dravet Syndrome, Lennox-Gastaut Syndrome

Boston Scientific Signs an Agreement with BPEA to Acquire Lumenis Surgical Business

Published: Mar 4, 2021 | Tags: Boston Scientific, Signs, Agreement, BPEA, Acquire, Lumenis, Surgical Business

Amgen Reports Results of Blincyto (blinatumomab) in P-III Study for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients

Published: Mar 3, 2021 | Tags: Amgen, Reports, Results, Blincyto (blinatumomab), P-III, Study, Relapsed Acute Lymphoblastic Leukemia, Pediatric, Patients

BeiGene's Brukinsa (zanubrutinib) Receives Health Canada's Approval for Waldenström's Macroglobulinemia

Published: Mar 3, 2021 | Tags: BeiGene, Brukinsa (zanubrutinib), Receives, Health Canada, Approval, Waldenström's Macroglobulinemia

Fusion to Acquire Ipsen's IPN-1087 to Expand its Pipeline of Radiopharmaceuticals

Published: Mar 3, 2021 | Tags: Fusion, Acquire, Ipsen, IPN-1087, Expand, Pipeline,  Radiopharmaceuticals

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

Published: Mar 3, 2021 | Tags: G1 Therapeutics and Boehringer Ingelheim, Launch, Cosela (trilaciclib), US

Biocon Biologics and Viatris Receive CHMP's Positive Opinion for Abevmy (biosimilar, bevacizumab)

Published: Mar 3, 2021 | Tags: Biocon Biologics and Viatris, Receive, CHMP, Positive Opinion, Abevmy (biosimilar, bevacizumab)

AbbVie Signs a Purchase Right Agreement to Acquire Mitokinin

Published: Mar 3, 2021 | Tags: AbbVie, Signs, Purchase, Right, Agreement, Acquire, Mitokinin

Veru to Advance VERU-111 in P-III Study for COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Published: Mar 2, 2021 | Tags: Veru, Advance, VERU-111, P-III, Study, COVID-19, Patients, High Risk, Acute Respiratory Distress Syndrome

AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

Published: Mar 2, 2021 | Tags: AstraZeneca, Collaborates, Junshi, Commercialize, Toripalimab, China

Hologic to Acquire Diagenode for ~$159M

Published: Mar 2, 2021 | Tags: Hologic, Acquire, Diagenode, ~$159M

Samsung Bioepis Initiates P-I Study of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Published: Mar 2, 2021 | Tags: Samsung Bioepis, Initiates, P-I, Study, SB17, Proposed, Biosimilar, Stelara (ustekinumab)

Merck Reports the US FDA's Acceptance of NDA for Review of Gefapixant to Treat Refractory or Unexplained Chronic Cough

Published: Mar 2, 2021 | Tags: Merck, Reports, US, FDA, Acceptance, NDA, Review, Gefapixant, Treat, Unexplained, Chronic Cough

Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant

Published: Mar 2, 2021 | Tags: Merck KGaA, Sign, Exclusive, Worldwide, License, Agreement, Debiopharm, Xevinapant

BMS Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP's Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma

Published: Mar 1, 2021 | Tags: BMS, Opdivo (nivolumab), Cabometyx (cabozantinib), Receive, CHMP, Positive Opinion, 1L, Treatment, Advanced Renal Cell Carcinoma

Regeneron's Ab Cocktail (casirivimab + imdevimab) Receives the CHMP's Positive Opinion to Treat COVID-19

Published: Mar 1, 2021 | Tags: Regeneron, Ab Cocktail (casirivimab + imdevimab), Receives, CHMP, Positive, Opinion, Treat, COVID-19

Johnson & Johnson Receives the US FDA's EUA for COVID-19 Vaccine

Published: Mar 1, 2021 | Tags: Johnson & Johnson, Receives, US, FDA, EUA, COVID-19, Vaccine

AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR Trial for Severe Asthma

Published: Mar 1, 2021 | Tags: AstraZeneca and Amgen, Report, Results, Tezepelumab, P-III, NAVIGATOR, Trial, Severe Asthma

Roivant to Acquire Silicon Therapeutics for ~$450M

Published: Mar 1, 2021 | Tags: Roivant, Acquire, Silicon Therapeutics, ~$450M

BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

Published: Mar 1, 2021 | Tags: BridgeBio and Origin, Nulibry (fosdenopterin), Receives, US, FDA, Approval, First, Therapy, Reduce, Risk, Mortality, Patients, MoCD Type A

Related Post: PharmaShots Weekly Snapshots (Feb 22 - 26, 2021)